Navigation Links
Human, animal vaccine development goal of hepatitis E virus research
Date:3/7/2008

Blacksburg, Va.--Dr. X.J. Meng, of Blacksburg, Va., a professor of virology in the Virginia-Maryland Regional College of Veterinary Medicines Department of Biomedical Sciences and Pathobiology at Virginia Tech, has been awarded two research grants totaling almost $3 million from the National Institutes of Health (NIH) to study the hepatitis E virus (HEV). The ultimate goal of the work is to develop a vaccine to protect people and animals from Hepatitis E.

HEV is an important human pathogen, according to Meng. The disease caused by HEV, Hepatitis E, is a major public health problem in developing countries in Asia and Africa, and in Mexico. Hepatitis E is also endemic in the United States and many other industrialized countries, according to Meng. Although the overall mortality associated with HEV infection is generally low (less than 1 percent), it can be as high as 28 percent in infected pregnant women. Currently, there is no vaccine to prevent Hepatitis E.

The major obstacle for Hepatitis E research and vaccine development has been the lack of a practical animal model system for HEV research and the inability to propagate HEV in cell culture, explains Meng. With funding from NIH, Mengs group recently discovered two HEV-related animal viruses in the United States: swine hepatitis E virus (swine HEV) from pigs, and avian hepatitis E virus (avian HEV) from chickens. It has since been demonstrated that swine HEV can cross species barriers and infect humans, and that human HEV can infect pigs. Hepatitis E is now regarded as a zoonotic disease.

With the discoveries of the two new animal viruses, Mengs group quickly developed a pig model and a chicken model to study the hepatitis E virus. Prior to Mengs discoveries of the two animal hepatitis E viruses, scientists were forced to use non-human primates in order to study the disease. Conducting HEV research with primates at one of the NIH regional primate centers is expensive and contains some ethical concerns, according to Meng, so developing the new animal models will be a major step forward in the research.

The first NIH grant, entitled Mechanism of hepatitis E virus replication and pathogenesis, conveys total funding of $1,561,797 and the co-investigators are Dr. Patrick G. Halbur, and Dr. Yao-Wei Huang. The second grant, entitled A chicken model to study hepatitis E virus pathogenesis includes funding of $1,266,300 and the co-investigators are Dr. F. William Pierson, Dr. Tanya LeRoith, and Dr. Yao-Wei Huang. Both grants begin on March 1, 2008 and will support four years of work.

The grants will enable researchers to learn more about the molecular mechanisms of HEV replication and pathogenesis by using pigs and chickens as animal model systems. Specifically, the researchers will study how HEV causes hepatitis, the gene(s) that are responsible for virulence, the mechanism(s) for cross-species infection by HEV, and how to attenuate the virus for vaccine development purpose. Ultimately, the researchers hope to develop a vaccine against this important human pathogen.

Mengs laboratory in the colleges Center for Molecular Medicine and Infectious Disease (CMMID) is considered one of the worlds leading Hepatitis E virus research centers. Previously, he had received nearly $2 million dollars from the NIH to study the same virus. Meng currently chairs the Hepatitis E Virus study group on the International Committee on Taxonomy of Viruses (ICTV).

Funded by the United States Department of Agriculture and several private corporations, Mengs lab also studies several economically important animal viruses including porcine circovirues, and porcine reproductive and respiratory syndrome virus. Recently, Mengs lab successfully developed the first USDA fully-licensed vaccine, Suvaxyn PCV2 One Dose, against porcine circovirus associated diseases, an economically important swine disease worldwide. Virginia Tech has licensed the vaccine to Wyeth Inc. and Fort Dodge Animal Health Inc., and the vaccine is currently on the U.S. and Canadian markets, and has now begun to enter the global markets. The vaccine is saving millions of dollars each year for the swine industry.


'/>"/>

Contact: Jeff Douglas
jdouglas@vt.edu
540-231-7911
Virginia Tech
Source:Eurekalert

Related medicine news :

1. Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation
2. Pain Management For Pets, Key Strategies For Veterinarians - Live Webcast to Veterinarians, March 13, 7:00 p.m. to 8:00 p.m. (EDT) Via Morris Animal Foundation
3. Researchers create first chikungunya animal model
4. Animal Planet Pet Video to Provide 2 Million Free Training DVDs to New Pet Parents of Adopted Shelter Dogs and Cats
5. U.S. Seeks to Limit Animal Testing of Toxic Chemicals
6. Chicago Tribune Does Story on Canine Cancer, Morris Animal Foundation (MAF) Effort to Find a Cure - MAF Can Provide Information - Local Angles for a Feature Story
7. Photo: Animal Rescue League of Boston Receives $3 Million Grant to Establish a Center for Shelter Dogs
8. The Blue Buffalo Foundation for Cancer Research Sponsors Six Morris Animal Foundation Cancer Studies
9. Anpath Group, Inc. Announces Advancements with Animal Care Line
10. Wild Animal Crunch(TM) Helps Moms Tame Families Hunger
11. Plan expedites alternatives to animal testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology: